Fierce Biotech
FDA approves Denali’s Hunter syndrome drug, handing rare disease community a win
The FDA has approved Denali Therapeutics’ enzyme replacement therapy for a genetic lysosomal storage disease after a string of high-profile rejections for rare disease candidates.